RO60

Summary

RO60 (Ro60, Y RNA binding protein, HGNC:11313) is a protein-coding gene on chromosome 1q31.2, encoding RNA-binding protein RO60 (P10155). RNA-binding protein that binds to misfolded non-coding RNAs, pre-5S rRNA, and several small cytoplasmic RNA molecules known as Y RNAs.

Enables RNA binding activity. Involved in cellular response to interferon-alpha and regulation of gene expression. Located in cilium; cytosol; and nuclear body. Part of ribonucleoprotein complex.

Source: NCBI Gene 6738 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 120 total
• Druggable target: yes
• MANE Select transcript: NM_001173524

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11313
Approved symbol	RO60
Name	Ro60, Y RNA binding protein
Location	1q31.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000116747
Ensembl biotype	protein_coding
OMIM	600063
Entrez	6738

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 19 protein_coding, 1 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000367441, ENST00000367443, ENST00000367444, ENST00000367445, ENST00000367446, ENST00000400968, ENST00000415442, ENST00000432079, ENST00000460715, ENST00000469214, ENST00000506303, ENST00000512587, ENST00000874665, ENST00000874666, ENST00000874667, ENST00000874668, ENST00000874669, ENST00000874670, ENST00000874671, ENST00000938562, ENST00000948784

RefSeq mRNA: 6 — MANE Select: NM_001173524 NM_001042369, NM_001042370, NM_001173524, NM_001173525, NM_001331020, NM_004600

CCDS: CCDS1379, CCDS41449, CCDS41450, CCDS53451, CCDS86042

Canonical transcript exons

ENST00000400968 — 9 exons

Exon	Start	End
ENSE00001614938	193059612	193059776
ENSE00001678331	193084579	193091219
ENSE00003492139	193076501	193076647
ENSE00003518607	193081364	193081480
ENSE00003545812	193082186	193082299
ENSE00003611020	193069034	193069634
ENSE00003628009	193082562	193082708
ENSE00003639502	193075820	193076040
ENSE00003657335	193076913	193077050

Expression profiles

Bgee: expression breadth ubiquitous, 295 present calls, max score 99.23.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 39.5781 / max 531.7029, expressed in 1822 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
7472	37.7833	1820
201855	0.9819	524
7469	0.6625	408
7473	0.1504	44

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
nipple	UBERON:0002030	99.23	gold quality
lateral globus pallidus	UBERON:0002476	99.20	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	99.14	gold quality
inferior olivary complex	UBERON:0002127	99.10	gold quality
inferior vagus X ganglion	UBERON:0005363	99.10	gold quality
cranial nerve II	UBERON:0000941	99.04	gold quality
sperm	CL:0000019	98.98	gold quality
medulla oblongata	UBERON:0001896	98.98	gold quality
substantia nigra pars reticulata	UBERON:0001966	98.98	gold quality
renal medulla	UBERON:0000362	98.96	gold quality
trabecular bone tissue	UBERON:0002483	98.95	gold quality
urethra	UBERON:0000057	98.93	gold quality
visceral pleura	UBERON:0002401	98.91	gold quality
trigeminal ganglion	UBERON:0001675	98.89	gold quality
subthalamic nucleus	UBERON:0001906	98.82	gold quality
pylorus	UBERON:0001166	98.76	gold quality
globus pallidus	UBERON:0001875	98.73	gold quality
parietal pleura	UBERON:0002400	98.73	gold quality
superior vestibular nucleus	UBERON:0007227	98.72	gold quality
saphenous vein	UBERON:0007318	98.71	gold quality
pericardium	UBERON:0002407	98.68	gold quality
vena cava	UBERON:0004087	98.68	gold quality
mammary duct	UBERON:0001765	98.64	gold quality
male germ cell	CL:0000015	98.63	gold quality
medial globus pallidus	UBERON:0002477	98.61	gold quality
ventral tegmental area	UBERON:0002691	98.56	gold quality
epithelium of mammary gland	UBERON:0003244	98.56	gold quality
penis	UBERON:0000989	98.55	gold quality
cardia of stomach	UBERON:0001162	98.55	gold quality
substantia nigra pars compacta	UBERON:0001965	98.53	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

177 targeting RO60, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-128-3P	99.95	71.17	2484

Literature-anchored findings (GeneRIF, showing 20)

• In viitro RNA chaperone activity of SSA2 was studied. (PMID:15928345)
• The structural organization and Zn2+-dependent subdomain interactions involving autoiantigenic epitopes in the RBBC region of SS-A were studied. (PMID:15964842)
• Increased Ro/SSA 60 and La/SSB mRNA expression in minor salivary glands in primary Sjogren’s syndrome (pSS) suggest that these 2 autoantigens, but not Ro/SSA 52, are involved in tissue-specific autoimmune response in pSS. (PMID:17552056)
• interactions between Ro-Y5 and L5-5S RNPs establish 5S RNA as a target of quality control (PMID:18056422)
• results demonstrate that Ro 60 functions as a novel receptor for beta(2)GPI on the surface of apoptotic cells. The formation of Ro 60-beta(2)GPI complexes may protect against anti-Ro 60 autoantibody-mediated tissue injury. (PMID:19248095)
• Activation of Toll-like receptors by fetal factor Ro60-associated single-stranded RNA particles is relevant in autoimmune-associated congenital heart block, where the obligate maternal factor is an anti-SSA/Ro autoantibody. (PMID:20089705)
• dichotomy of human autoantibody responses against mutually exclusive determinants linked to a single domain of a systemic autoantigen and supports a model in which tolerance is broken by different immunogenic forms of Ro 60 (PMID:20131295)
• 60 kD Ro and nRNP A frequently initiate human lupus autoimmunity (PMID:20224770)
• conclude that RNPs containing hY RNAs and Ro60, La or nucleolin are not required for the function of hY RNAs in chromosomal DNA replication in a human cell-free system, which can be mediated by Y RNAs outside of these RNPs (PMID:21060685)
• these data indicate that ZBP1 may function as an adapter to export the Ro/Y3 RNA complex from nuclei. (PMID:22114317)
• Findings indicate a relentless turnover of short-lived clonotypic variants, masquerading as long-lived Ro60 humoral autoimmunity. (PMID:23644453)
• The Y3 RNA moiety of the Ro60 ribonucleoprotein plays a critical role in the pathogenesis of fetal cardiac injury by altering the subcellular location of Ro60 autoantibodies. (PMID:23698747)
• TROVE2 is a novel target of miR-128 in astrocytoma tissues and the expression of TROVE2 is increased with the pathological stages increasing. (PMID:26307612)
• These findings establish a link among the lupus autoantigen Ro60, Alu retroelements, and type I interferon. (PMID:26382853)
• Significant relationships were found between clinical and laboratory manifestations of autoimmune and rheumatic diseases with different patterns of antibodies to anti-Ro52, anti-Ro60 and anti-La. (PMID:26725021)
• Because the Ro60 ribonucleoprotein (RNP) is a clinically important target of autoantibodies in patients with rheumatic diseases such as Sjogren’s syndrome, systemic lupus erythematosus, and neonatal lupus, this review discusses potential roles for Ro60 RNPs in the initiation and pathogenesis of systemic autoimmune rheumatic disease. [review] (PMID:31084369)
• strengthens the anti-inflammatory effect via macrophage polarization by estrogen induction in abdominal aortic aneurysm (PMID:31863777)
• Noncoding Y RNAs regulate the levels, subcellular distribution and protein interactions of their Ro60 autoantigen partner. (PMID:32469055)
• Identification of a unique anti-Ro60 subset with restricted serological and molecular profiles. (PMID:32852779)
• IL-33/ST2 Activation Is involved in Ro60-Regulated Photosensitivity in Cutaneous Lupus Erythematosus. (PMID:35909659)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ro60	ENSDARG00000089225
mus_musculus	Ro60	ENSMUSG00000018199
rattus_norvegicus	Ro60	ENSRNOG00000003434
drosophila_melanogaster	CG10803	FBGN0029666
caenorhabditis_elegans		WBGENE00004405

Protein

Protein identifiers

RNA-binding protein RO60 — P10155 (reviewed: P10155)

Alternative names: 60 kDa SS-A/Ro ribonucleoprotein, Ro 60 kDa autoantigen, Sjoegren syndrome antigen A2, Sjoegren syndrome type A antigen, TROVE domain family member 2

All UniProt accessions (5): P10155, D6RDN1, D6RE09, G5E9R9, H0Y9N5

UniProt curated annotations — full annotation on UniProt →

Function. RNA-binding protein that binds to misfolded non-coding RNAs, pre-5S rRNA, and several small cytoplasmic RNA molecules known as Y RNAs. Binds to endogenous Alu retroelements which are induced by type I interferon and stimulate porinflammatory cytokine secretion. Regulates the expression of Alu retroelements as well as inflammatory genes. May play roles in cilia formation and/or maintenance.

Subunit / interactions. Identified in a IGF2BP1-dependent mRNP granule complex containing untranslated mRNAs. Found in a complex with PUF60 and Y5 RNA. Interacts with RAB11FIP5.

Subcellular location. Cytoplasm.

Domain organisation. The horseshoe-shaped TROVE domain is built with 7 helical HEAT-like repeats, and is closed by the VWFA-like domain giving rise to a ring-shaped monomer. Single-stranded RNA is bound in the positively charged central cavity. The MIDAS-like motif in the VWFA-like domain binds divalent metal cations.

Miscellaneous. Antibodies against normal cellular SSA2 protein are found in sera from patients with systemic lupus erythematosus (SLE).

Similarity. Belongs to the Ro 60 kDa family.

Isoforms (5)

UniProt ID	Names	Canonical?
P10155-1	Long	yes
P10155-2	Short, 60E2
P10155-3	3
P10155-4	4
P10155-5	5

RefSeq proteins (6): NP_001035828, NP_001035829, NP_001166995, NP_001166996, NP_001317949, NP_004591 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008858	TROVE_dom	Domain
IPR036465	vWFA_dom_sf	Homologous_superfamily
IPR037214	TROVE_dom_sf	Homologous_superfamily
IPR040322	TROVE2	Family
IPR056800	vWA_Ro60	Domain

Pfam: PF05731, PF25045

UniProt features (19 total): modified residue 5, splice variant 5, binding site 3, sequence conflict 2, region of interest 2, chain 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P10155-F1	93.42	0.86

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 378; 380; 445

Post-translational modifications (5): 224, 359, 1, 4, 19

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 214 (showing top): BROWNE_HCMV_INFECTION_30MIN_DN, BORCZUK_MALIGNANT_MESOTHELIOMA_UP, BROWNE_HCMV_INFECTION_6HR_DN, SWEET_KRAS_ONCOGENIC_SIGNATURE, GOBP_RESPONSE_TO_PEPTIDE, MORF_UBE2N, GOBP_TRANSCRIPTION_BY_RNA_POLYMERASE_III, THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_DN, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_1, GOBP_RESPONSE_TO_INTERFERON_ALPHA, RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_UP, MILI_PSEUDOPODIA_HAPTOTAXIS_UP, MORF_CCNI, SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A4, BLALOCK_ALZHEIMERS_DISEASE_UP

GO Biological Process (8): immune system development (GO:0002520), transcription by RNA polymerase III (GO:0006383), smoothened signaling pathway (GO:0007224), response to UV (GO:0009411), regulation of gene expression (GO:0010468), cellular response to interferon-alpha (GO:0035457), cilium assembly (GO:0060271), cell projection organization (GO:0030030)

GO Molecular Function (3): RNA binding (GO:0003723), U2 snRNA binding (GO:0030620), metal ion binding (GO:0046872)

GO Cellular Component (7): nucleoplasm (GO:0005654), cytosol (GO:0005829), cilium (GO:0005929), nuclear body (GO:0016604), ribonucleoprotein complex (GO:1990904), nucleus (GO:0005634), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
immune system process	1
system development	1
DNA-templated transcription	1
cell surface receptor signaling pathway	1
response to light stimulus	1
gene expression	1
regulation of macromolecule biosynthetic process	1
response to interferon-alpha	1
cellular response to cytokine stimulus	1
axoneme assembly	1
intraciliary transport involved in cilium assembly	1
cilium organization	1
protein localization to cilium	1
organelle assembly	1
trans-Golgi to periciliary membrane compartment transport	1
plasma membrane bounded cell projection assembly	1
ciliary transition zone assembly	1
cellular component organization	1
nucleic acid binding	1
snRNA binding	1
cation binding	1
nuclear lumen	1
cytoplasm	1
intraciliary transport particle	1
membrane-bounded organelle	1
plasma membrane bounded cell projection	1
nucleoplasm	1
intracellular membraneless organelle	1
protein-containing complex	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1018 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RO60	TRIM21	P19474	998
RO60	SSB	P05455	903
RO60	CALR	P27797	815
RO60	SNRNP70	P08621	812
RO60	CENPB	P07199	805
RO60	EXOSC10	Q01780	764
RO60	APOH	P02749	688
RO60	DNAJB1	P25685	635
RO60	SNRPN	P14648	616
RO60	HARS2	P49590	596
RO60	HTN3	P15516	588
RO60	NUCLEOLIN	P19338	584
RO60	HARS1	P12081	576
RO60	MORC3	Q14149	571
RO60	SNRPC	P09234	526

IntAct

54 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
SNRPD2	GEMIN2	psi-mi:“MI:0914”(association)	0.710
IGF2BP1	IGF2BP3	psi-mi:“MI:0914”(association)	0.640
	XPO1	psi-mi:“MI:0914”(association)	0.530
ELAVL2	IGF2BP3	psi-mi:“MI:0914”(association)	0.530
RO60	SSB	psi-mi:“MI:0914”(association)	0.530
ELAVL2	CASC3	psi-mi:“MI:0914”(association)	0.530
SRSF3	CASC3	psi-mi:“MI:0914”(association)	0.530
Rrbp1	PIPSL	psi-mi:“MI:0914”(association)	0.350
JUN	TPM3	psi-mi:“MI:0914”(association)	0.350
DND1	RPSA2	psi-mi:“MI:0914”(association)	0.350
Mecom	ESYT2	psi-mi:“MI:0914”(association)	0.350
CUL3	PXDNL	psi-mi:“MI:0914”(association)	0.350
LRRK2		psi-mi:“MI:0914”(association)	0.350
ELAVL2	IGF2BP3	psi-mi:“MI:0914”(association)	0.350
	PSMD11	psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350
N	FLG	psi-mi:“MI:0914”(association)	0.350
IFTAP	GNPAT	psi-mi:“MI:0914”(association)	0.350
SRF	GPC4	psi-mi:“MI:0914”(association)	0.350
GABARAPL2		psi-mi:“MI:0914”(association)	0.350
GABARAPL1		psi-mi:“MI:0914”(association)	0.350
GABARAP		psi-mi:“MI:0914”(association)	0.350
RAF1	EIF3CL	psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350

BioGRID (225): TROVE2 (Affinity Capture-RNA), ATL3 (Co-fractionation), SUB1 (Co-fractionation), UQCRQ (Co-fractionation), TROVE2 (Affinity Capture-MS), TROVE2 (Affinity Capture-MS), RNY3 (Protein-RNA), RNY1 (Protein-RNA), TROVE2 (Affinity Capture-MS), TROVE2 (Affinity Capture-MS), TROVE2 (Affinity Capture-MS), TROVE2 (Affinity Capture-MS), TROVE2 (Affinity Capture-MS), TROVE2 (Affinity Capture-MS), TROVE2 (Affinity Capture-MS)

ESM2 similar proteins: A2Z4C5, A7X672, A7X680, B0K012, B8AJL9, B8AR41, B9SQI7, E0CSI1, O08848, O75794, O81770, O82730, P0C0T1, P10155, P42694, P57060, P93115, Q0J035, Q10PL5, Q13572, Q1PET6, Q28559, Q2PG37, Q2R483, Q2YDG3, Q33BI9, Q3U2J5, Q5F477, Q5F480, Q5R9U9, Q62834, Q69QJ7, Q6AY91, Q6DFV5, Q75GI4, Q7SY78, Q80YV4, Q8BYN3, Q8CII2, Q8LB01

Diamond homologs: O08848, P10155, P42700, Q27274, Q9RUW8

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 63 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
MAPK6/MAPK4 signaling	5	14.8×	2e-03
mRNA Splicing	5	11.9×	4e-03
mRNA Polyadenylation	6	11.5×	2e-03
mRNA Splicing - Major Pathway	8	9.5×	7e-04
Processing of Capped Intron-Containing Pre-mRNA	5	8.9×	8e-03
Dengue Virus-Host Interactions	8	7.9×	1e-03
Metabolism of RNA	7	6.3×	5e-03

GO biological processes:

GO term	Partners	Fold	FDR
mRNA splicing, via spliceosome	6	10.0×	4e-03
RNA splicing	6	9.6×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

120 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	99
Likely benign	3
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1225 predictions. Top by Δscore:

Variant	Effect	Δscore
1:193070546:ACC:A	acceptor_gain	1.0000
1:193076597:G:GT	donor_gain	1.0000
1:193076908:TCTA:T	acceptor_loss	1.0000
1:193076909:CTA:C	acceptor_loss	1.0000
1:193076910:TA:T	acceptor_loss	1.0000
1:193076911:A:AG	acceptor_gain	1.0000
1:193076912:G:GG	acceptor_gain	1.0000
1:193076912:G:GT	acceptor_loss	1.0000
1:193076912:GGCTC:G	acceptor_gain	1.0000
1:193081362:A:AC	acceptor_loss	1.0000
1:193081362:A:AG	acceptor_gain	1.0000
1:193081363:G:GG	acceptor_gain	1.0000
1:193081363:G:GT	acceptor_loss	1.0000
1:193081363:GA:G	acceptor_gain	1.0000
1:193081363:GAC:G	acceptor_gain	1.0000
1:193081363:GACA:G	acceptor_gain	1.0000
1:193081438:T:TA	donor_gain	1.0000
1:193081439:A:AA	donor_gain	1.0000
1:193081479:TGG:T	donor_loss	1.0000
1:193081480:GGTG:G	donor_loss	1.0000
1:193081481:G:GG	donor_gain	1.0000
1:193081482:T:A	donor_loss	1.0000
1:193082181:TTCA:T	acceptor_loss	1.0000
1:193082182:TCA:T	acceptor_loss	1.0000
1:193082183:CAG:C	acceptor_loss	1.0000
1:193082295:GTCAG:G	donor_gain	1.0000
1:193082297:CAGGT:C	donor_loss	1.0000
1:193082298:AGGTA:A	donor_loss	1.0000
1:193082299:GGT:G	donor_loss	1.0000
1:193082300:G:GG	donor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000020906 (1:193072247 G>A), RS1000031152 (1:193069901 T>C), RS1000245454 (1:193089989 A>G), RS1000794759 (1:193082411 C>T), RS1000834910 (1:193063202 G>A,C,T), RS1001319740 (1:193090591 G>T), RS1001370353 (1:193075408 A>G), RS1001384552 (1:193089313 T>C), RS1001464016 (1:193068874 G>A), RS1001468613 (1:193083987 G>A), RS1001476266 (1:193073640 C>A,T), RS1001605408 (1:193091037 T>A), RS1001749056 (1:193069055 A>G,T), RS1001863576 (1:193070374 G>A), RS1001972939 (1:193078327 G>A,T)

Disease associations

OMIM: gene MIM:600063 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066968 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

4 potent at pChembl≥5 of 4 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.69	Kd	20.52	nM	CHEMBL5653589
7.69	ED50	20.52	nM	CHEMBL5653589
5.66	Kd	2184	nM	CHEMBL3752910
5.66	ED50	2184	nM	CHEMBL3752910

PubChem BioAssay actives

2 with measured affinity, of 4 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149662: Binding affinity to human TROVE2 incubated for 45 mins by Kinobead based pull down assay	kd	0.0205	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149662: Binding affinity to human TROVE2 incubated for 45 mins by Kinobead based pull down assay	kd	2.1838	uM

CTD chemical–gene interactions

55 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, decreases methylation	2
Cadmium Chloride	decreases expression, increases expression	2
FR900359	increases phosphorylation	1
bisphenol F	increases expression	1
dicrotophos	decreases expression	1
chloroacetaldehyde	decreases expression	1
methylmercuric chloride	decreases expression	1
alpha-pinene	decreases expression, increases abundance, affects cotreatment	1
bisphenol A	increases expression	1
sodium arsenate	decreases expression	1
trichostatin A	decreases expression	1
2-butenal	decreases expression	1
nickel chloride	decreases expression	1
ferrous chloride	increases expression	1
methacrylaldehyde	affects cotreatment, decreases expression, increases abundance	1
beta-methylcholine	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
nutlin 3	affects cotreatment, increases expression	1
pentabrominated diphenyl ether 100	increases expression	1
hexabrominated diphenyl ether 153	increases expression	1
jinfukang	decreases expression	1
LDN 193189	affects cotreatment, increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Rosiglitazone	decreases expression	1
Resveratrol	increases expression, affects cotreatment	1
Cidofovir	decreases expression	1
Acrolein	affects cotreatment, decreases expression, increases abundance	1
Air Pollutants	affects cotreatment, decreases expression, increases abundance	1
Arsenic	affects methylation	1
Vehicle Emissions	increases expression, increases abundance	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652704	Binding	Binding affinity to human TROVE2 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TU83	HAP1 TROVE2 (-) 1	Cancer cell line	Male
CVCL_TU84	HAP1 TROVE2 (-) 2	Cancer cell line	Male
CVCL_TU85	HAP1 TROVE2 (-) 3	Cancer cell line	Male
CVCL_TU86	HAP1 TROVE2 (-) 4	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.